[Genetically engineered drugs and their application with the example of erythropoietin].
Over the past two decades, many genetically engineered drugs have been developed and approved for the treatment of patients. Typically, these drugs are characterized by a high and specific activity in the presence of optimal safety. They include hormones, enzymes, growth and coagulation factors, antibodies as well as vaccines. All these proteins are generated using recombinant DNA technology. An expression vector with the gene encoding for the protein of interest is introduced into an appropriate microorganism or cell line. The biochemical machinery of the host cell then translates the genetic information into the corresponding protein. Large scale production of the recombinant drugs uses biotechnological processes. The genetically modified organisms are grown in bioreactors from which the desired protein is finally isolated and purified. This review focuses on the production and clinical application of recombinant erythropoietin in the areas of nephrology, hemato-oncology and elective surgery.
Donatz
V
V
Janssen-Cilag GmbH, Neuss.
Zahner
J
J
D001709:Biotechnology / Q000379:methods / Q000639:trends; D004274:DNA, Recombinant / Q000235:genetics; D004921:Erythropoietin / Q000627:therapeutic use*; D005818:Genetic Engineering / Q000379:methods / Q000639:trends; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*
D004274:DNA, Recombinant; D011994:Recombinant Proteins; D004921:Erythropoietin